Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
BACKGROUND: In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained virologic response 12 weeks after actual end of treatment (SVR12) in chronic hepatitis C virus (HCV) genotype 1-infected patients. SVR12 rates were generally lower in the 2-DAA regimen SMV + TMC647055/RTV with or without ribavirin. The objective of this study was to identify and characterise pre-existing and emerging resistance-associated variants (RAVs) in patients enrolled in study TMC647055HPC2001.
METHODS: HCV population sequencing analyses were performed on baseline isolates from all patients (n = 90) and post-baseline isolates from patients with virologic failure (n = 22). In addition, deep sequencing and phenotypic analyses were performed on selected baseline and post-baseline isolates.
RESULTS: The majority of patients with virologic failure had emerging RAVs to all study drugs at the time of failure: in all 22 patients SMV RAVs emerged at NS3 positions 80, 155, 156 and/or 168, consistent with the known SMV resistance profile. Emerging TMC647055 RAVs at NS5B position 495 were detected in the majority of patients (16/22), and all 5 patients who failed the 3-DAA regimen had emerging JNJ-56914845 RAVs at NS5A positions 30 and/or 31. While at the end of study emerging SMV and TMC647055 RAVs were no longer observed by population sequencing in 40% (8/20) and 62.5% (10/16) of patients with follow-up data available, respectively, emerging JNJ-56914845 RAVs were still detected in all (5/5) patients.
CONCLUSIONS: Virologic failure in the 2- and 3-DAA combinations was, in the majority of patients, associated with the emergence of RAVs to all study drugs. While emerging SMV and TMC647055 RAVs became undetectable during follow-up, JNJ-56914845 RAVs in NS5A were still observed at end of study.
TRIAL REGISTRATION NUMBER: NCT01724086 (date of registration: September 26, 2012).
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Virology journal - 14(2017), 1 vom: 31. Mai, Seite 101 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Vijgen, Leen [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 21.02.2018 Date Revised 26.03.2024 published: Electronic ClinicalTrials.gov: NCT01724086 Citation Status MEDLINE |
---|
doi: |
10.1186/s12985-017-0760-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM272498645 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM272498645 | ||
003 | DE-627 | ||
005 | 20240326233456.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12985-017-0760-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1348.xml |
035 | |a (DE-627)NLM272498645 | ||
035 | |a (NLM)28569206 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Vijgen, Leen |e verfasserin |4 aut | |
245 | 1 | 0 | |a Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845 |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 21.02.2018 | ||
500 | |a Date Revised 26.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a ClinicalTrials.gov: NCT01724086 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained virologic response 12 weeks after actual end of treatment (SVR12) in chronic hepatitis C virus (HCV) genotype 1-infected patients. SVR12 rates were generally lower in the 2-DAA regimen SMV + TMC647055/RTV with or without ribavirin. The objective of this study was to identify and characterise pre-existing and emerging resistance-associated variants (RAVs) in patients enrolled in study TMC647055HPC2001 | ||
520 | |a METHODS: HCV population sequencing analyses were performed on baseline isolates from all patients (n = 90) and post-baseline isolates from patients with virologic failure (n = 22). In addition, deep sequencing and phenotypic analyses were performed on selected baseline and post-baseline isolates | ||
520 | |a RESULTS: The majority of patients with virologic failure had emerging RAVs to all study drugs at the time of failure: in all 22 patients SMV RAVs emerged at NS3 positions 80, 155, 156 and/or 168, consistent with the known SMV resistance profile. Emerging TMC647055 RAVs at NS5B position 495 were detected in the majority of patients (16/22), and all 5 patients who failed the 3-DAA regimen had emerging JNJ-56914845 RAVs at NS5A positions 30 and/or 31. While at the end of study emerging SMV and TMC647055 RAVs were no longer observed by population sequencing in 40% (8/20) and 62.5% (10/16) of patients with follow-up data available, respectively, emerging JNJ-56914845 RAVs were still detected in all (5/5) patients | ||
520 | |a CONCLUSIONS: Virologic failure in the 2- and 3-DAA combinations was, in the majority of patients, associated with the emergence of RAVs to all study drugs. While emerging SMV and TMC647055 RAVs became undetectable during follow-up, JNJ-56914845 RAVs in NS5A were still observed at end of study | ||
520 | |a TRIAL REGISTRATION NUMBER: NCT01724086 (date of registration: September 26, 2012) | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Genotype 1 | |
650 | 4 | |a Hepatitis C virus | |
650 | 4 | |a JNJ-56914845 | |
650 | 4 | |a Simeprevir | |
650 | 4 | |a TMC647055/ritonavir | |
650 | 7 | |a 27-cyclohexyl-12,13,16,17-tetrahydro-22-methoxy-11,17-dimethyl-10,10-dioxide-2,19-methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclo docosine-8,18(9H,15H)-dione |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Carbamates |2 NLM | |
650 | 7 | |a GSK2336805 |2 NLM | |
650 | 7 | |a Heterocyclic Compounds, 4 or More Rings |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a Ribavirin |2 NLM | |
650 | 7 | |a 49717AWG6K |2 NLM | |
650 | 7 | |a Simeprevir |2 NLM | |
650 | 7 | |a 9WS5RD66HZ |2 NLM | |
650 | 7 | |a Valine |2 NLM | |
650 | 7 | |a HG18B9YRS7 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
700 | 1 | |a Thys, Kim |e verfasserin |4 aut | |
700 | 1 | |a Vandebosch, An |e verfasserin |4 aut | |
700 | 1 | |a Van Remoortere, Pieter |e verfasserin |4 aut | |
700 | 1 | |a Verloes, René |e verfasserin |4 aut | |
700 | 1 | |a De Meyer, Sandra |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Virology journal |d 2004 |g 14(2017), 1 vom: 31. Mai, Seite 101 |w (DE-627)NLM151772509 |x 1743-422X |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2017 |g number:1 |g day:31 |g month:05 |g pages:101 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12985-017-0760-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2017 |e 1 |b 31 |c 05 |h 101 |